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Cross-Cultural Inequivalence of Dermatology-
Specific Health-Related Quality of Life Instruments
in Psoriasis Patients
Tamar Nijsten1, David M. Meads2, John de Korte3, Francesca Sampogna5, Joel M. Gelfand4, Katia Ongenae6,
Andrea W. Evers7 and Matthias Augustin8
The dermatology life questionnaire index (DLQI) and the Skindex are the most commonly used dermatology-
specific health-related quality of life (HRQOL) instruments. Although these tools are used in international
surveys and clinical trials, the cross-cultural equivalence of their items has not been documented. We used
differential item functioning (DIF), which is part of the Rasch model, to assess the impact of cultural background
on the items of the DLQI and Skindex-29 and-17. The data of the 450 psoriasis patients, who attended in- and
outpatient dermatology centers, was collected retrospectively from five European and one US center. The DLQI
and Skindex-29 scales did not fit the Rasch model (Po0.0008) and 10/10 of the DLQI and 19/29 of the Skindex-29
items displayed significant DIF. Although the psychosocial scale of the Skindex-17 fitted the Rasch model, half or
more of the items of the psychosocial (6/12) and the symptom scale (4/5) showed significant DIF across
countries. These findings suggest that psoriasis patients from different countries respond differently to a
substantial proportion of DLQI and Skindex items despite having the same level of underlying HRQOL
impairment. Therefore, these instruments should not be used in their current form in international studies.
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INTRODUCTION
Patient reported outcomes such as health-related quality of
life (HRQOL) are increasingly important in the assessment of
disease severity and evaluating the effect of interventions. In
dermatology, HRQOL impairment is pivotal because most
skin diseases are chronic and intermittent but not life
threatening or physically disabling. Moreover, several studies
have shown that clinical disease severity does not necessarily
correlate well with patients’ perspectives of disease severity
and HRQOL impairment (Sampogna et al., 2004).
The dermatology life questionnaire index (DLQI) (Finlay
and Khan, 1994) and Skindex-29 (Chren et al., 1997) are the
most commonly used dermatology-specific HRQOL instru-
ments. Most large dermatological clinical trials are multi-
national and include multiple sites located in 10 or more
countries and use the change in DLQI score as an end point.
In contrast to widely used HRQOL tools such as the Short
Form-36 and -12, WHOQOL-100, EuroQoL-5D (Wagner
et al., 1998; Gandek et al., 1998; Skevington, 2002; Prieto
et al., 2003), no cross-cultural equivalence studies of the
DLQI and Skindex-29 have been performed to test whether
items’ responses are independent of cultural background or
not. A recent validation study of the Skindex-17 (Nijsten
et al., 2006a) in psoriasis patients from three European
countries demonstrated that nationality did affect how
patients, with the same amount of psychosocial impairment,
responded to some items (Both et al., submitted) confirming
that it is important to test for cultural differences in
dermatology-related HRQOL tools as well before they are
used in multinational studies (Anderson et al., 1993, 1996;
Bullinger et al., 1993a; McHorney and Fleishman, 2006).
The objective of this analysis was to use differential item
functioning (DIF) (Angoff, 1993; McHorney and Fleishman,
2006), which is set within the framework of the Rasch
unidimensional measurement, to study the effect of cultural
background (e.g., nationality) on retrospectively collected
DLQI and Skindex data from five European countries and the
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US. It was not the intention of this study to adjust these
instruments for potential cultural differences or to differenti-
ate between a suboptimal translational process and true
measurement unequivalence.
RESULTS
Study population
For each country, 75 psoriasis patients were included, except
for the Skindex-29 in the US (n¼72). Table 1 presents the
origin of the study patients, the nationality of the psoriasis
patients, and the mean scores of the DLQI and the Skindex-
29. Patients from Germany and Ireland reported greater
impact of psoriasis on their lives than those from other
countries. Of the included patients, the mean score of the
DLQI was 7.1 (SD 6.4, interquartile range: 1.0–13.0) and 32.9
(SD 23.8, interquartile range: 13.0–48.0) for functioning, 46.7
(SD 24.9, interquartile range: 28.0–63.0) for emotions, and
54.5 (SD 23.3, interquartile range: 39.0–71.0) for symptom’s
scale of the Skindex-29. The age and gender distribution
between countries was similar (male percentage ranged
between 44.0 and 54.5% and the mean age ranged between
43.8 and 47.1 years, respectively), except that German
psoriasis patients were younger (mean age of 38.6 and 37.2
years).
Dermatology life quality index
Overall, the DLQI significantly misfitted the Rasch model
(mean item interaction 0.00, SD 0.45; mean person interac-
tion –1.29, SD 1.28; item–trait interaction, Po0.0001) but
had an excellent person separation index of 0.88. After
stratification by country, the DLQI misfitted the Rasch model
in half the countries (Table S1). After combining all countries,
half of the items demonstrated significant individual misfit
(items 1, 3, 5, 8, and 10), three items had reversed thresholds
but no DIF was seen across gender and age. All items had
uniform DIF and four items also had nonuniform DIF across
cultures (Table S2). The item characteristic curve (ICC) of
item 1 shows that Belgian, Dutch, and Italian patients
reported more psoriasis-related skin symptoms than expected
and than those from US, UK, and Germany (Figure 1). Italians
and Belgians experienced significantly less often ‘‘problems
with loved ones’’ (item 8) and ‘‘sexual difficulties’’ (item 9)
because of their psoriasis compared with remaining patients
with similar levels of disability measured by the DLQI.
For the 10 DLQI items, psoriasis patients from specific
countries were not persistently scoring higher than others
(data not shown). However, the ICC of Italians, Belgians, and
often the Dutch were closely aligned in majority of the items
(8/10) both below and above the expected curve as were
those of the UK and US. On average, the German ICC was
either more in the middle or close to those of the English-
speaking patients.
Skindex-29
Overall, the items of the Skindex-29 fitted the Rasch model
(item fit mean 0.00, SD 0.52) but the persons did not
(person fit mean –0.47, SD 0.94), which resulted in a
significant item–trait interaction statistic (Table S3). The
person separation index was excellent (0.95). Of the 29
items, seven showed significant item misfit, nine threshold
Table 1. Countries of residence of patients included for the DLQI and Skindex-29 scales and the mean scores1
DLQI Skindex-29
Country of
residence
Mean score (SD,
25th–75th percentile) Reference
Functioning mean
score (SD, 25th and
75th percentile)
Emotions mean score
(SD, 25th and 75th
percentile)
Symptoms mean
score (SD, 25th and
75th percentile) Reference
Belgium 6.9 (5.6, 3.0–11.0) Ongenae et al.,
20052
—3 —3 —3 —3
Germany 17.7 (6.6, 13.0–23.0) Augustin et al.,
19992
33.2 (29.0, 17.0
and 48.0)
46.8 (25.1, 25.0
and 68.0)
53.8 (24.0, 36.0
and 71.0)
Augustin et al.,
20042
Ireland —3 —3 47.6 (20.7, 31.0
and 55.5)
62.0 (23.1, 48.0
and 79.5)
75.3 (16.6, 64.0
and 89.0)
de Korte et al.,
20054
Italy 7.4 (5.1, 4.0–10.0) Sampogna
et al., 20042
35.8 (23.9, 17.0
and 50.0)
47.4 (22.9, 28.0
and 65.0)
47.7 (21.4, 32.0
and 57.0)
Sampogna et al.,
20042
The Netherlands 8.0 (6.3, 3.0–11.0) Evers et al.,
20052
21.7 (18.4, 8.0
and 29.0)
33.4 (17.5, 20.0
and 45.0)
53.2 (18.5, 43.0
and 64.0)
de Korte et al.,
20054
UK 11.7 (5.9, 6.0–16.0) McKenna et al.,
20032
23.6 (21.7, 4.0
and 40.0)
40.4 (23.2, 23.0
and 58.0)
53.7 (21.4, 39.0
and 68.0)
de Korte et al.,
20054
USA1 13.6 (5.0, 12.0–17.0) McKenna et al.,
20052
33.0 (26.3, 10.0
and 54.0)
50.6 (27.7, 30.0
and 73.0)
44.1 (21.7, 29.0
and 57.0)
Joel Gelfand2,5
DLQI, dermatology life questionnaire index; SD, standard deviation.
1Each country contributed 75 randomly selected psoriasis patients to the analyses, except US, which contributed 72 patients for the Skindex. The Skindex-
17 was derived from the Skindex-29 instrument. Range of DLQI is 0–30 and Skindex-29 is 0–100.
2Patient recruitment at university centers.
3No data was obtained for these countries.
4Patient recruitment at treatment centers.
5Unpublished data.
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disorder, and two items had significant DIF for age. Although
no nonuniform DIF was detected across countries (except
item 16), more than a third of the 29 items showed significant
uniform DIF (Table S4).
Psoriasis patients from specific countries were not
persistently scoring higher than others, except US, British,
and Italian patients who scored 10 or more times more
extreme (higher or lower) than expected, whereas the patients
of other countries scored more often in accordance with the
expected. Also, especially the US and to a lesser extent British
and Italian patients scored substantially higher on the
emotion items. In contrast to the DLQI, no clear ICC
associations were seen between countries.
If analyzed separately, the functioning scale did not fit the
overall model, four items showed significant misfit, one item
had threshold disorder, and two items had DIF for age and
gender (Table S3). However, across countries, 7/12 items
showed significant differences (Table S5). For example,
people from the UK reported significantly more often that
psoriasis affected their social life (item 5) but despite that they
stayed at home significantly less frequently (item 8) compared
with Italian patients with similar amounts of functioning
impairment.
The emotions scale of the Skindex-29 misfitted the Rasch
model (item mean interaction 0.00, SD 0.56; person mean
interaction –034, SD 1.30; item trait interaction, Po0.0001;
person separation index 0.91). Only item 9 misfitted, two
items had reversed thresholds, and one demonstrated DIF for
age and gender. In contrast, significant uniform DIF across
country was seen in 7/10 items (Table S5). No nonuniform DIF
was present. Despite similar levels of emotional impairment,
the Germans and Italians were more angry and depressed, the
Dutch more ashamed and annoyed, the Italians and Americans
more often embarrassed, and the British, Irish, and American
patients were more frequently frustrated compared with the
other patients from different countries.
Of the symptom scale, the item and person mean
interaction fitted the model well (0.00, SD 0.62 and –0.07,
SD 1.25, respectively) but with a significant item–trait
interaction (P¼0.0008). The person separation index was
0.87. Only item 18 showed significant misfit, items 7 and 16
had disordered thresholds and one item with DIF was
detected across age and gender. All items had uniform DIF
across cultures (Table S5). Psoriasis patients from the UK,
Netherlands, and Germany were significantly more often
‘‘bothered by water’’ (item 16) than those from Philadelphia
(US), and Italy. Italians reported more often symptoms such as
burning and stinging, irritation, bleeding, and that they had a
sensitive skin compared with patients from most other
countries.
Skindex-17
The 12 items of the psychosocial scale of the Skindex-17
fitted the Rasch model relatively well (item mean interaction
0.00, SD 0.61; person mean interaction 0.51, SD 0.79;
item–trait interaction, P¼0.07) (Table S4). The person
separation index was excellent (0.91). None of the items
had individual misfit, threshold order, or DIF across gender
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Figure 1. ICC plotted against country. (a) Bothered by water (Skindex-17),
(b) frustrated (Skindex-29), (c) desire to be with people (Skindex-17),
(d) itches (Skindex-17), (e) itchy, sore, painful, or stinging (DLQI), and
(f) work around the house (DLQI).
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and age, except item 6, which showed significant DIF across
age levels (patients less than 30 years had significantly felt
more often depressed than older patients). Items 4, 5, 8, 20,
and 22 demonstrated different responses than expected
across cultures (the last four items all ask about direct
interactions with others) (Table S5). Despite different scoring
categories, items 5 (social life), 8 (stay home), 20 (embar-
rassed), and 22 (frustrated) show patterns comparable with
that seen in the functioning and emotions subscales of the
Skindex-29 (Figure 1). Despite a changed scoring system and
underlying construct, the observed ICC patterns of the items
of the Skindex-17’s psychosocial scale and Skindex-29 were
comparable.
Of the Skindex-17, the mean item and person interaction
of the symptom scale was good (0.00, SD 0.94 and 0.15, SD
1.45) but the item–trait interaction was significant (P¼0.001)
and the person separation index was 0.78 (Table S2). Item 18
(irritated) showed significant individual misfit but none of the
five items had threshold disorder or DIF across gender and
age. All items showed uniform DIF across cultures, item 16
showed nonuniform DIF also (Table S5). As seen in the
symptom subscale of the Skindex-29, Italians were more
frequently bothered by psoriasis symptoms and the German
patients reported significant fewer itches despite similar
levels of underlying construct (Figure 1). Also, patients from
Manchester (UK) scored lower on most symptom-related
items than excepted compared with patients from other
nations. The observed ICC patterns of the symptom items of
the Skindex-17 and those of the Skindex-29 showed less
variation but were comparable.
Sensitivity analyses
Restricting the DIF analyzes across cultures to native English-
speaking psoriasis patients (Ireland, UK, and US) changed the
results substantially for Skindex-29. Instead of 16/29 display-
ing significant DIF, only six had significant DIF across these
three countries (items 3, 8, 16, 20, 26, and 29). The same
restrictions improved the psychosocial scale (only two (items
1 and 21) instead of 6/12 displayed significant DIF) and the
symptom scale of the Skindex-17 (not all items, only items 16
and 18 remained significant) as well. Restricting the analyses
to the non-native English-speaking patients (Dutch, Germans,
and Italians) did not substantially reduce the number of items
with significant DIF across culture (data not shown) suggest-
ing that the improvement by restricting it to English-speaking
patients is not only because of reduced sample size and
number of categories. For the DLQI, no significant differences
were detected between British and American psoriasis
patients. However, among the non-native English-speaking
patients, nationality had a significant effect on 7/10 items.
Limiting the DIF analyzes to northern European countries
(Germany, Ireland, The Netherlands, and UK) decreased the
number of items with DIF across nations to nine (items 4, 6,
8, 12, 15, 16, 20, 22, and 25) for the Sklindex-29. Of the
Skindex-17 psychosocial scale, 6/12 items (items 4, 5, 6, 8,
20, and 22) displayed significant DIF and all items, except
item 26, displayed DIF in the symptom scale. Including only
northern European countries in the DLQI analyses showed
that seven items displayed uniform and five nonuniform DIF.
To test whether the overall fit of the Skindex-17 was owing to
reduced number of items, we randomly selected 12 items
form the emotions and functioning scale and five from the
symptom scale of the Skindex-29 and demonstrated that both
item sets significantly misfitted the Rasch model (item–trait
interaction¼ 159.8, df¼72, and Po0.0001 and item–trait
interaction¼ 66.5, df¼30, and Po0.0001, respectively).
DISCUSSION
Unidimensionality
The DLQI and the Skindex-29 are the most commonly used
dermatology-specific HRQOL instruments. However, in
psoriasis patients, they significantly misfit the Rasch model,
in part owing to individual item misfit, threshold disorder,
and DIF, confirming other findings suggesting that these
instruments fail to fulfill fundamental measurement require-
ments such logical ordering of scoring categories, unidimen-
sionality, and lack of impact of external factors on its items
(Nijsten et al., 2006a, b). In contrast, the psychosocial and, to
a lesser extent, the symptom scale of the Skindex-17 behaved
well in this multinational sample of psoriasis patients. This is
probably because of the fact that the Skindex-17 was
developed using the Rasch models.
Cross-cultural differences
In addition to suboptimal psychometric properties, the
majority of the items of the DLQI and Skindex dysfunctioned
between psoriasis patients from different cultural back-
grounds. Although it is not uncommon to spot many DIF
items in HRQOL instruments and the effect of the cross-
cultural DIF in this analysis needs to studied (Hambleton,
2006; McHorney and Fleishman, 2006), the observed cross-
cultural inequivalence may result in true measurement bias
where multinational study data is combined (Anderson et al.,
1993, 1996; Bullinger et al., 1993a, b). Also, more qualitative
research into what causes DIF is needed to minimize its effect
(McHorney and Fleishman, 2006). Therefore, the Skindex
and DLQI should not be used in multinational (psoriasis)
studies in their current form and, if use continues, attempts
should be made to adjust cross-cultural DIF. All items of the
DLQI and about half of the Skindex-29 and -17 showed DIF
across the seven countries suggesting that despite similar
amounts of underlying HRQOL impairment patients’ nation-
ality influenced scoring of these items. Similar items of the
DLQI and Skindex such as symptom-related items confirmed
the findings in the separate instruments. Interestingly, it
seemed that the responses of patients from Latin-oriented
countries (Belgium and Italy) clustered as well as those of
English-speaking patients (UK and US). This was confirmed
by sensitivity analysis restricted to the native English-speaking
patients suggesting that the relevance, meaning, attitude, and
expression differ for several items across nations. Completing
a HRQOL questionnaire can be considered a ‘‘social
encounter’’ and, as such, is governed by social rules and
norms, which are culturally dependent. Because all ques-
tionnaires were either the original or translated version using
guidelines (Guillemin et al., 1993; Wild et al., 2005), it is
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unlikely that the cultural differences are because of transla-
tional issues only. However, it is interesting that lesser
differences were detected among native English-speaking
psoriasis patients, which may be owing to cultural equiva-
lence, the use of the original versions of the tools, and/or
both. Emotions such as embarrassment, self-consciousness,
frustration, shame, irritation, humiliation, annoyance, and
anger may be adequately translated but still have different
meanings and interpretations across cultures (e.g., false
cognates (meaning of words is not same in different
languages) or homographs (words are spelled alike but have
different meanings) may play a role in this issue). It seems that
patients from some countries such as Italy and Belgium report
less difficulties showing physical intimacy, which is reflected
in several items, than those from other countries arguing that
there are psychological differences such as identification,
coping, and negation between patients from different
cultures. This is in accordance with US studies showing that
it is less stigmatizing for Hispanics to admit symptoms of
psychological distress and for blacks to exhibit greater social
desirability, resulting in under-reporting (McHorney and
Fleishman, 2006). Although German psoriasis patients had
high overall impairment levels, they reported significantly
less symptoms, Italians reported a high frequency of most
types of symptoms, and cultural inequivalence was detected
in all symptom (sub)scales suggesting that the interpretation
of skin symptoms varies substantially between countries.
Another explanation of the observed inequivalence may be
that scoring categories are interpreted differently and/or
response patterns such as an extreme response style differ
between cultures, but collapsing the five response categories
of the Skindex to three categories, as is done in the Skindex-
17, did not substantially reduce the observed differences.
In the light of the increasing importance of HRQOL
evaluation in clinical trials and public health studies of
chronic non-life-threatening diseases such as most skin
diseases and the often multinational nature of these studies,
we need a dermatology-specific instrument that is in line with
the current psychometric standards and can be used across
cultures. Despite the enormous research effort in the field of
HRQOL in dermatology, the overwhelming majority of these
studies are descriptive and very few methodologically
oriented. Of the DLQI and the Skindex-29, which were
published 15 years or more ago and are widely used, crucial
instrument characteristics such as minimal clinical impor-
tance differences and cultural equivalence have yet not been
reported. For now, the DLQI is considered the standard
HRQOL measurement in dermatology by many and has
introduced HRQOL to mainstream dermatology, but it is a
first-generation instrument. The creation and refinement of
the Skindex-29 lifted HRQOL in dermatology to another level
making it a second-generation instrument. Third-generation
HRQOL instruments are developed according to guidelines,
use item response theory models to assure fundamental
measurement requirements, and are tested in patients that
differ in demographic, including cultural background, and
disease characteristics. The Skindex-17 was an attempt to
upgrade the Skindex to a third-generation instrument but
despite the fact that it fitted the Rasch model reasonably well,
responses by psoriasis patients to half of its items were
influenced by patients’ nationality.
The need of a dermatology-specific HRQOL instrument
Are we in need of a new dermatology-specific HRQOL
instrument? A psychometrically good and widely accepted
dermatology-specific HRQOL instrument is pivotal because
of comparative reasons and because several studies have
shown that they provide additional information to generic
HRQOL tools. However, more studies are needed to clarify
which generic tool (e.g., Short Form-36 and-12, EuroQol-5D,
Nottingham Health Profile, Sickness Impact Profile) is
preferable in all or specific skin disease and how they
behave across cultures in dermatologic patients. To come to a
third-generation HRQOL instrument that is widely accepted,
existing instruments have to be adjusted and refined or a new
instrument has to be developed. Although it is not the
objective of this study, DIF misfit can be adjusted for by
altering scoring categories for these items and/or using item-
split techniques for uniform DIF (Angoff, 1993; Tennant et al.,
2004). These approaches may be useful if sufficient items
measure a unidimensional construct (e.g., fit the Rasch
model) and a minority of items have uniform DIF to be
adjusted for a limited number of external factors such as age,
gender, cultural background, and skin disease. These basic
assumptions make it extremely complicated to adjust the
DLQI or Skindex-29 because large number of their items
demonstrate some kind of misfit. In addition to the observa-
tion that quantifying skin-related symptoms depends on
diagnosis (Nijsten et al., 2006a), the measurement of
symptoms is greatly influenced by cultural background
suggesting that it should not be compared in international
patient groups with different skin diseases. Therefore,
adjustment of the five items of the symptom scale of the
Skindex-17 is very complex and may not be worthwhile. Of
the tools and scales tested in this study, the psychosocial
scale of the Skindex-17 may be the only one eligible to be
adjusted for because of the good overall fit, a smaller number
of items with individual misfit, threshold disorder, and DIF.
Strengths and limitations
This is the first cultural equivalence study for the DLQI and
Skindex in a large international sample using state-of-the-art
psychometric techniques. The importance of cross-cultural
comparison studies is illustrated by the fact that some very well-
established HRQOL instruments such as the Short Form-36 and
-12 have been tested for it and it was included in the design of
the development study of the EuroQOL-5D and WHOQOL-
100. Moreover, large clinical trials are almost always multi-
center studies with patients from multiple countries and include
HRQOL (most often the DLQI in dermatology) as a primary or
secondary outcome. However, this study suggest that the
current dermatology-specific instruments do not meet the new
standards in psychometrics, except may be the psychosocial
scale of the Skindex-17 (McHorney, 1997).
Although there are more traditional psychometric ap-
proaches to test for cross-cultural differences (Gandek et al.,
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1998), Rasch analysis is among the most commonly used
statistical methods in this type of studies (Prieto et al., 2003;
Roorda et al., 2004; Tennant et al., 2004). In addition to the
theoretical advantages of this technique, Rasch analysis was
especially interesting to use because it assumes sample-free
measurement. This implied that we were able to collect
patients retrospectively from different countries, clinical
settings, health-care systems, and demographic characteris-
tics, with varying degrees of psoriasis severity without
compromising the study findings. For example, differences
in clinical psoriasis severity among patients from six countries
should have no substantial impact on the study findings
because DIF analysis did not directly compare psoriasis
patients from the included nations but compared those
patients of different nations who have the same level of
underlying construct (i.e., HRQOL impairment). Because
sample size may affect the results of the analysis of variance
(ANOVA) analysis, which is used for DIF, (Wright and
Tennant (1996); Hambleton, 2006), we choose a priori
to create equally sized patient groups from several countries
to have about 500 eligible patients. The fit of each country to
the model should be interpreted with caution because of the
relatively small sample sizes. In contrast to the results of each
country separately, none of the analyses of the total study
population showed an overall fit to the model (this may also
be explained by the observed cultural differences). Also, a
Rasch analysis of a larger group of British psoriasis patients,
from which we randomly selected 75 observations, did show
significant misfit in contrast to our findings (McKenna et al.,
2004). However, a sample size of 75 is large enough to have
99% confidence that the parameter estimates are within
1 logit of the stable value (Linacre, 1994). The majority of the
study patients had moderate to severe psoriasis from
university and/or psoriasis treatment centers, which is
described in the references and confirmed by the high mean
DLQI and Skindex-29 scores. Because the sensitivity espe-
cially of the DLQI at the lower ends of the HRQOL spectrum
is likely to be low, it makes the study results more robust but
decreases their generalizibility. Additional prospective stu-
dies with a greater variety of skin diseases and cultural
backgrounds are needed to confirm our findings and study
the meaningfulness of DIF (e.g., comparing results of
unadjusted pooled scores with transformed scores to eradi-
cate DIF) (McHorney and Fleishman, 2006).
Conclusion
The importance of HRQOL measurement in dermatology
warrants more methodological studies to test existing
instruments and refine them, if possible, or create a new
tool that complies with its purposes. In the attempt to create a
tool that measures HRQOL impact in dermatology in a
scientific way, cultural differences should be taken into
account.
MATERIALS AND METHODS
Study population
We searched Pubmed to identify papers that included DLQI and/or
Skindex-29 data in psoriasis patients and peers interested in HRQOL
and psoriasis. Our aim was to have about 75 anonymous patients
with predominantly plaque-type psoriasis from more than five
countries along with their age and gender. Researchers with eligible
data were contacted and all but one provided their available data.
If collaborators provided a larger sample, a random sample of 75
patients was generated using random number-generator method to
conform to equal group size requirements for the ANOVA of the
residuals (Tabachnick and Fidell, 2001) because 75 was the smallest
group of patients from one country. Patients were excluded if two or
more items were not scored for the DLQI (Finlay and Khan, 1994)
and/or if more than 25% of the Skindex-29 items were not recorded
(Chren et al., 1997). No additional information on type of psoriasis,
presence of arthritis, and extent of disease was collected.
In brief, the DLQI consists of 10 items with four response
categories (range 0–30) (Finlay and Khan, 1994). The Skindex-29,
has 29 items (five response categories) divided over three subscales
(emotions, functioning, and symptoms) (Chren et al., 1997).
Although a composite score of the Skindex-29 has not been formally
studied and has little face validity (Chren, personal communication),
several studies have used it. Therefore, an overall score of the
Skindex-29 (converted to range between 0 and 100) was also
analyzed. The Skindex-17 is two-dimensional and the score of its
two scales (12 psychosocial items (range 0–24) and five symptom
items (range 0–10)) were derived from the Skindex-29 data after
rescoring the items appropriately (Nijsten et al., 2006a). For each of
the three instruments, a higher score indicates more HRQOL
impairment.
Statistical analysis
In general, the Rasch model is a unidimensional model developed in
the field of education, which asserts that the easier the item the more
likely it will be passed, and the more able the person, the more likely
they will pass an item compared with a less able person. The
probability that a person will affirm an item is a logistic function of
the difference between the person’s ability (or level of disease
severity) and the difficulty of the item (or the level of disease severity
represented in the item) and only a function of that difference. This
approach can also contribute to the issue of cross-cultural validity
and has been used in several studies (Prieto et al., 2003; Roorda
et al., 2004; Tennant et al., 2004). Responses to the scale’s items
should only depend on the amount of underlying construct (i.e.,
dermatology-specific HRQOL impairment) and not on external
factors such as cultural background (Angoff, 1993; McHorney and
Fleishman, 2006) (e.g., the score of any given DLQI item should not
be significantly different between UK and US patients who both have
a mean DLQI score of 10). Under the requirement that the ability
under consideration is unidimensional, if the item measures the
same ability across groups then, except for random variations, the
same proportion is found irrespective of the nature of the group for
whom a function is plotted. Items that do not yield the same item
response function for two or more groups display DIF and are
violating the requirement of unidimensionality. If the location of
items along the measurement construct should remain the same
across cultures, there is no significant DIF. Bonferroni corrections
were applied to the DIF statistics because of multiple testing for each
of the three instruments separately.
The statistical test used for detecting DIF is an ANOVA of the
person–item deviation residuals with person factors (e.g., country of
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residence) and class intervals (e.g., number of groups along the trait
and the number depends on the sample size with about 30–50
persons per group) as factors (Angoff, 1993), which is a well
accepted method to study DIF (Tennant et al., 2004). Two types of
DIF can be identified. With uniform DIF there is a constant
difference between groups in the probability in affirming a category
across the trait (ANOVA main effect) resulting in parallel ICCs. With
nonuniform DIF, the difference varies across trait (ANOVA interac-
tion effect) and results in a nonparallel and/or crossing ICC. The
importance of this difference is that uniform DIF can be corrected by
assigning different scores or weighing the scores for the person
factor, whereas nonuniform DIF cannot be corrected in existing
instruments. In addition to DIF across countries, overall fit to the
Rasch model, individual item fit, threshold order, and DIF across
gender and age were studied (Nijsten et al., 2006a). The Rasch
analysis was performed with RUMM2020 (RUMM Laboratory Pvt
Ltd, Perth, Australia).
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Table S1. Overall fit to the Rasch model, number of significant individual item
misfits, threshold disorder, and DIF for the DLQI for each country.
Table S2. DIF across countries for the DLQI.
Table S3. Overall fit to the Rasch model, number of significant individual item
misfits, threshold disorder, and DIF for the Skindex-29 and its scales for each
country.
Table S4. Overall fit to the Rasch model, number of significant individual item
misfits, threshold disorder, and DIF for the two scales of the Skindex-17 for
each country.
Table S5. DIF across countries for the Skindex-29 and Skindex-17.
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